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In recent years, wide ranging biomedical innovation has provided powerful new approaches for prevention, diagnosis and management of
diseases. In order to translate such innovation into effective practice, physicians must frequently update their knowledge base and skills
through continuing medical education and training. Medical Professional Societies, run as not-for-profit organizations led by peers, are
uniquely placed to deliver balanced, disease oriented and patient centred education. The medical industry has a major role in the develop-
ment of new, improved technology, devices and medication. In fact, the best innovations have been achieved through collaboration with
scientists, clinical academics and practicing physicians. Industry has for many years been committed to ensure the optimal and safe applica-
tion of its products by providing unrestricted support of medical education developed and delivered by international and national learned
societies. Recently adopted Codes of Practice for the Pharmaceutical and Device industry were intended to enhance public trust in the
relationship between biomedical industry and physicians. Unexpectedly, changes resulting from adoption of the Codes have limited the
opportunity for unconditional industry support of balanced medical education in favour of a more direct involvement of industry in
informing physicians about their products. We describe the need for continuing medical education in Cardiovascular Medicine in Europe,
interaction between the medical profession and medical industry, and propose measures to safeguard the provision of high quality, bal-
anced medical education.
...................................................................................................................................................................................................
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The need for continuing medical
education
Improved understanding of the biology of health and disease, including
molecular and genetic processes, as well as recent innovations in tech-
nology, biochemistry, biomedical engineering, and informatics have
provided physicians with powerful tools and methods for prevention,
diagnosis and management of diseases. This has reduced early mortality
from cardiovascular disease, improved life expectancy, and quality of
life, although the number of people living with chronic cardiac and vas-
cular conditions continues to grow.1 The ongoing development and
evaluation of these innovations necessitates continuous information,
education, and training of health care professionals to underpin appro-
priate use of disease classifications, diagnostic tools and new treatments
and to ensure that care is delivered sensibly, efficiently, and cost-
effectively. The medical industry has a major role in the development
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of new, improved technology, devices, and medication, often through
collaboration with scientists, clinical academics, and practicing physi-
cians. Continued cooperation is warranted to ensure development
and introduction into practice of future innovative treatment options.
There is important heterogeneity in culture and lifestyle, economic
prosperity and organization, funding and access to health care across
Europe and abroad. Disparities in organization, access to training and
education of health care professionals, in conjunction with societal fac-
tors, contribute to significant differences in morbidity and mortality from
cardiovascular disease. It is one of the tasks of the European Society of
Cardiology (ESC) to enable exchange about best cardiovascular care
between different countries thereby promoting best practice of cardio-
vascular medicine throughout Europe and beyond. The medical industry
supports training and education of physicians and other health care pro-
fessionals. However, the relationship between health care professionals
and the medical industry is complex, a consequence of the dominant
global model of private enterprise based innovation, research, and pro-
duction, and the absence of structural funding of continuing education of
physicians in most countries (Table 1). This document outlines a blue-
print for trustworthy, balanced education in cardiovascular medicine,
making use of the opportunities for collaboration with industry, to pro-
vide physicians with appropriate and unbiased information.
The circle of research, education,
and evaluation of medical practice
In order to promote its mission, to reduce the burden of cardiovascular
disease, the ESC has developed an extensive educational programme.
European Society of Cardiology-delivered education is firmly based on
evidence, summarized in the clinical practice guidelines. Guidelines are
updated at regular intervals. Evidence underpinning practice guidelines is
generated throughout the world in basic, translational, clinical, and epi-
demiological research projects. Furthermore, the ESC has introduced a
programme of registries [EURObservational Research Programme
(EORP)] to describe clinical practice patterns in Europe and beyond.
The data collected provide essential feedback about best practices,
needs assessments, and feedback on the success of educational pro-
grammes and training. This is represented in the ‘virtuous circle’ of
research, education, and medical practice. Moreover, the development
of guidelines, assessment of their implementation in the ‘real world’ and
of their impact on outcomes contributes to Health Technology
Assessment and provides key references for policy makers.3
It should be emphasized that in order to ensure complete inde-
pendence, the costs of guideline development are paid fully by the
ESC, using income from other activities as outlined in its annual
reports, while, in the absence of other sources of funding, educational
programmes and the registries are supported in part by industry. The
ESC has developed a robust and transparent contractual framework
and governance structure to enable unbiased planning and execution
of these activities in partnership with health care industry. Trust is the
guiding principle of this partnership between ESC, its constituent
bodies and members, health care industry, the public, and other
stakeholders. These structures are continuously developed and
updated with input from all stakeholders to ensure reliable and trust-
worthy activities (guideline development, education programmes,
and observational research).
Requirements for continuing
medical education in European
countries
Physicians and other health care professionals have a responsibility to
continuously update their knowledge and skills. Increasingly, this has
become a statutory obligation, e.g. retention of a specialty degree
often requires participation in approved educational activities that
provide the participant a defined number of so called ‘Continuing
Medical Education (CME) credits’ (Figure 1), as well as some reckon-
ing of numbers and outcomes of interventional procedures to retain
the qualification to practice these procedures.
Costs of continuing medical
education
Continuing medical education is currently obtained by attending con-
ferences (local, regional, national, international), online courses, in-
person training programmes, or reading and reviewing of scientific
papers. Providing continuous medical education to health care pro-
fessionals is a very costly undertaking, yet financial resources to
develop or participate in CME programmes are rarely provided by
health care providers or employers. Nevertheless Europeans, includ-
ing physicians and other health care professionals, have an expection
that education is provided free, in contrast with other countries
where costs for education are usually paid by individuals.
In Europe, meetings and conferences organized by professional
societies are the preferred form of external CME.4 To meet this
need, the ESC organizes a large annual congress, as well as a series of
sub-specialty congresses (Figure 2). Similar large scientific congresses
are run by professional societies in the USA and in Asia-Pacific. Most
National Cardiac Societies run annual scientific and education meet-
ings. The organization and delivery of such international and national
meetings incurs significant costs, covered by a combination of regis-
tration fees and from contributions by industry partners, which
organize marketing and information activities in conjunction with the
congress through exhibitions and satellite symposia (Table 2).
Medical Journals play an important role in CME and download vol-
ume is a reflection of their use by physicians for educational purposes
Table 1 The relationship between the medical profes-
sion and industry
• A well-structured, transparent relationship between the medical
profession and industry is essential for research and innovation,
and medical education.
• An ill-structured relationship between the medical profession
and industry risks inappropriate decision making that generates
cost, suboptimal treatment choices, and erosion of public trust
• The relationship between health care professionals and industry
is necessarily complex; simplistic or absolutist solutions are
unlikely to apply
2 The future of continuing medical education
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(Table 3). Subscribers pay the publisher either individually or indi-
rectly through institutional subscriptions (hospitals or universities).
Professional organizations often offer subscriptions as part of their
membership programmes. The costs of journals are partly recovered
from subscriptions, and also by advertisements and sales of reprints,
although the latter have become almost redundant with the on-line
availability of content. Scientists and clinicians in universities and
other institutions provide the content of the journals, usually without
reimbursement. They may even have to pay the publisher for extra
costs (e.g. colour figures) or to get manuscripts published in ‘open
access’ journals. They also provide content for textbooks such as the
series of ESC textbooks.
The health care industry and
continuing medical education
It should be appreciated that, notwithstanding the key shared objec-
tive of improving patient outcomes, the medical profession and the
health care industry differ fundamentally in their fiduciary duties. The
beneficiaries in the case of physicians are their patients and to some
extent their employers; while the principal beneficiaries of health
care companies are their shareholders or their owners. Industry has
Figure 1 European Society of Cardiology member countries with a formal continuing medical education programme.
217 460 650 1000
3200
6000
33 130
Figure 2 Annual congresses organized by European Society of
Cardiology, with attendance, 2016. *The annual congress of the
European Association for Cardiovascular Prevention and
Rehabilitation, scheduled for Istanbul in May, was cancelled due to
security concerns and a smaller event was arranged at the European
Heart House in June. There were 1349 attendees at the 2015
EuroPrevent congress in Lisbon. Source: European Society of
Cardiology Annual Report 2017.
Table 2 Medical education: costs, funding, and
barriers
• Live meeting costs: rental of meeting facilities, organization,
preparation (frequently voluntary) of materials by speakers, staff
• Online course costs: recording and broadcasting, dedicated
on-line platform, interactivity features (webinars etc), faculty
preparation and delivery time (frequently voluntary), hardware,
software, staff
• Participants’ costs: time from work, registration fees, travel and
accommodation.
• Sources of funding: Registration fees; Medical Industry; Grants
(research, training or professional development) from
Professional Medical Societies, Government, Health care
Institutions; Health Care Providers’ personal funds; tax relief
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a principal duty to promote use of their products, in effect precluding
them from having a direct role in the provision of balanced and
unbiased education. Logically and ethically, high quality and unbiased
education that guides the best overall management of a patient must
also be in the interest of an industry that places patient well-being at
the centre of its mission (Table 4).
The phrase ‘if the product is free, you are the product’ is often used
to describe online services and information financed through advertis-
ing, but this principle also applies to medical educational programmes.
Programmes that are entirely run and funded by industry partners,
who have to justify the cost with an impact on revenue (‘return on
investment’), are at very high risk of taking a biased perspective.
Nevertheless, defining educational objectives, aligning the content with
independent, evidence-based guidelines, organizing buy-in from differ-
ent stakeholders and allowing an independent broker to co-ordinate
and plan the programme are features that can enable a high quality pro-
gramme that is indirectly funded by industry. A perceptive audience
interested in content that is tailored to their educational needs may
want to invest in education, either directly (personal fees) or through
their employers. In addition, health care providers, insurance companies
or national health care systems have a genuine obligation and interest
to invest in unbiased medical education and training. Hospitals or medi-
cal practices are, after all, knowledge-based institutions that rely on
highly skilled, well-trained workers to deliver high quality and safe care.
Support by industry for CME carries the risk of bias and unwanted
influence of industry on physicians, potentially influencing choice of
pharmaceutical agents or therapeutic devices and treatment patterns.
In many countries, this has led to regulation of such support. In 2012,
the European Commission published the ‘List of Guiding Principles
Promoting Good Governance in the Pharmaceutical Sector’
(Platform on Ethics & Transparency)’.5 This in turn led to the devel-
opment by the European Federation of Pharmaceutical Industries
and Associations (EFPIA), the representative organization for the
Pharmaceutical Industry in Europe, and by its medical device equiva-
lent (MedTech Europe), of specific Codes of Conduct regarding
industry interaction with health care professionals.6,7 These codes
closely mirror the guiding principles of the European Commission’s
document. In essence, both codes outline measures to minimize inap-
propriate interactions with physicians and other health care profes-
sionals, provide guidance on the nature and amount of financial
support and the venue and nature of meetings for which support
may be granted. However, no reference is made to direct provision
of medical education by industry in these documents.
A key provision in the MedTech code, implemented since January
2017, has been discontinuation of direct individual support of physi-
cians to attend meetings organized by professional societies or uni-
versities. Yet MedTech will support grants to third parties to
organize conferences and educational courses. European Federation
of Pharmaceutical Industries and Associations has produced a sepa-
rate Code for Transparency in the relationship between the
Pharmaceutical Industry and Health Care Professionals8 outlining
measures to publish details of all finances provided to individual prac-
titioners on their subsidiaries websites at national level. The code
.................................................................................................
Table 3 European Society of Cardiology journals:
impact factor and cumulative number of downloads
ESC journal title 2016 journal
impact factor
2016 full text
downloads
European Heart Journal 20.212 More than 13.5 million
full text downloadsEuropean Journal of Heart
Failure
6.968
European Heart Journal-
Cardiovascular Imaging
5.990
Cardiovascular Research 5.878
Eurointervention (Europa
Organization owned)
5.193
EP Europace 4.521
European Journal of Preventive
Cardiology
3.606
European Journal of
Cardiovascular Nursing
2.763
European Heart Journal
Supplements
0.896
European Heart Journal Acute
Cardiac Care
No IF yet
European Heart Journal
Quality of Care & Clinical
Outcomes
No IF yet
European Heart Journal
Cardiovascular
Pharmacotherapy
PubMed listed
ESC Heart Failure No IF yet
Source: European Society of Cardiology Annual Report 2017.
Table 4 Health care industry and continuing medical
education
• Involvement with industry in medical education has been permit-
ted on the basis of safeguards being taken
• Fiduciary duty of doctors is to their patients, the duty of industry
is to owners/shareholders
• Industry supported or delivered programmes inherently risk
favouring their product to comply with its fiduciary duty
• The quality and unbiased nature of medical education should be a
concern to physicians, and other stakeholders interested in ensur-
ing safe and effective care (employers/insurance industry/patients)
• Guidance for the interaction between the medical industry and
health care professionals include the European Commission’s ‘List
of Guiding Principles Promoting Good Governance in the
Pharmaceutical Sector’ (Platform on Ethics & Transparency)
20125; followed by codes of conduct from EFPIA,6,8 Medtech
Europe7 and the BioMed Alliance.9
• Effect of new industry codes of conduct has been paradoxical
and counterintuitive: discontinuation of direct support of physi-
cians to attend meetings of professional societies or universities,
but continued support of physicians to attend company educa-
tion/training courses and courses run by contracted medical com-
munication and medical education companies.
4 The future of continuing medical education
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allows for continued support to be provided for physicians to partici-
pate in third party educational activities. The Alliance for Biomedical
Research in Europe (BioMed Alliance), representing 27 medical pro-
fessional societies in Europe, including the ESC, published its own
Code of Conduct in 2015, outlining the principles for the ethical con-
duct of doctors in their relationship with the health care industry in
the different fields of joint interest, including medical education.9
The expected outcome of these codes was to enshrine and
formalize a transparent, ethical and productive relationship
between the health care industry and physicians that would build
public trust that has been at the core of educational programmes
developed by ESC.
Education programmes organised
by industry
There is a regulatory obligation to ensure safe use of medicinal prod-
ucts,10 and EU legislation indicates that risk control measures for
manufacturers should include, where appropriate, training for users
of medical devices.11 Such product related training should be distin-
guished from unbiased education about disease processes, diagnosis
and treatment. However, the development of educational, disease
oriented programmes aiming at CME by health care industry alone or
in partnership with employers has been proposed.12 The Global
Alliance for Medical Education (GAME—www.game-cme.org) was
approached for endorsement of such programmes, but its Board
decided against. As outlined above, the fundamentally different goals
of health care industry and learned societies render such industry-
organized programmes biased by nature. Despite the conflicts inher-
ent in direct industry provided education, its growth remains a real
prospect. In fact, direct industry provided education exists in a num-
ber of forms, run through industry funded institutes, educational
foundations, ‘Excellence Programmes’ and through Medical
Education and Communication companies.
Education programmes organized
by medical professional
organizations
A very strong argument can be made that medical professional asso-
ciations are best placed to provide CME. Both at national and interna-
tional level, these associations have access to unparalleled and
diverse expertise, are unbiased by nature and governance, transpar-
ent in their goals, respected and representative of their constituent
bodies, owned by their members, and comprise a network of mem-
bers that can ensure dissemination of information and accessibility. In
claiming this role, medical professional associations are bound to
uphold the highest ethical standards and to verify that presentations
are truly unbiased. It should also be appreciated that their annual con-
gresses are much more than just educational events or an exposition
of recent scientific progress. They provide a unique opportunity to
network and engage at a personal level with colleagues from around
the world to exchange views, to learn, to engage in credentialing
activities such as examinations as well as to promote continuing
educational activities at national and local levels. The opportunity for
young physicians to listen and interact with experienced colleagues
has played a central role in encouraging them to actively engage in
knowledge acquisition and generation. Thus, congresses provide a
unique platform to ‘learn from each other’.
Accreditation of continuing
medical education
Continuing medical education accreditation is required to provide
CME credits that are increasingly necessary for physicians to fulfil their
statutory obligations. Thus, accreditation authorities play a pivotal role
in recognizing appropriate, unbiased CME programmes. Most national
and international CME accreditation authorities have published
criteria for accreditation of events.13–16 European Accreditation
Council for Continuing Medical Education (EACCMEVR ) recently
updated their guidance, which clearly states that ‘all funding from
sponsors must be provided as an unrestricted educational grant,
free of any attempt to influence the programme, individual ses-
sions, subjects for discussion, content or choice of faculty mem-
bers’.13 It is an obligation of the organizers of medical education
to ensure that governance is in place to guarantee meaningful
implementation in practice.
Despite these rules, medical education and communication compa-
nies provide a means for industry to organize medical education closely
aligned to their agenda, yet one step removed, and so may be eligible
for CME accreditation by many authorities that depend on accredita-
tion activity for income. The credibility of CME programmes depends
on delivery of unbiased education, requiring a continuous review and
independent governance of programmes. The ESC organizes such
review through its independent, volunteer-based governance structure
and from its constituent bodies and members, and integrates feedback
into continuous programme development in a transparent process.
Collaboration of European
Society of Cardiology and industry
related to medical education
The collaboration between medical societies and industry in medical
education has long been a source of discussion and debate.17,18 Some
have advocated a total prohibition of industry involvement.19 The
most prevalent opinion, shared by ESC, supports a pragmatic
approach that maintains a partnership with industry in a clear gover-
nance framework that includes rigorous transparency, and strict rules
to avoid commercial bias in individual content.19,20
The ESC appreciates the support for CME from industry and real-
izes that, under the current regulations, new modes of support must
be explored, including grants to the ESC, designed to support individ-
ual participants to attend specific educational programmes and grants
to develop educational programmes, registries (EORP) or other spe-
cific educational products. The ESC may also apply for long-term sup-
port (5 or 6 years) for topic-oriented educational programmes based
on ESC guidelines, followed by a registry to assess the extent of
adherence to the guidelines, which in turn informs subsequent
The future of continuing medical education 5
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updates of these guidelines and leads to improved educational pro-
grammes (Figure 3).
To preserve and build an effective continuing medical education
programme, that is independent and unbiased, but that recognizes
and benefits from a transparent, valid, and clearly defined relationship
with medical industry, several steps must be taken:
• First, the health care industry must be convinced that a transpar-
ent and respectful collaboration with the medical profession which
continues to adhere to the principles of truly unbiased independ-
ent medical education is in the best interest of patients, the medi-
cal profession and the industry.
• Second, medical professionals attending programmes organized by,
or on behalf of industry should keep in mind that the presentations
are inherently biased. They must understand that independent
CME by their professional organizations is to be preferred, unless
specific product related information or device specific training is
sought. The ESC will continue to work with the Taskforce on
Medical Education of the BioMed Alliance to promote independ-
ent CME programmes across all medical specialties in Europe.
• Third, CME accreditation authorities must consistently apply their
own rules. Organizers of CME programmes must verify that pre-
sentations by scientists and clinicians are unbiased. Acknowledging
that abolishing all conflict of interest is neither possible nor, argu-
ably, desirable, a robust and meaningful method of declaring the
conflict should be developed. The widespread practice of present-
ing a slide for a few seconds at the start of a presentation is not a
meaningful exercise.
• Fourth, the ESC and its constituents should refrain from endorsing
programmes developed and provided by industry.
• Fifth, European and National authorities who demand that physi-
cians and other health care professionals undertake regular CME
should be involved in the discussion as to what alternative
approaches can be taken to resource this very costly undertaking.
• Sixth, there may be some recourse to the European
Commission’s Platform on Ethics & Transparency to counter
industry’s recent proposition to engage directly in medical educa-
tion as an unintended and undesirable outcome of its work.
It should be understood that despite all reasonable precautions to
ensure the independence of an educational event or programme,
individual speakers might still be subject to bias due to their relation-
ship with industry. In the end, it is the responsibility of each organizer
and faculty member to provide factually correct and reliable
information in whatever programme they participate, whatever the
setting, be it organized by or on behalf of industry or a professional
organization such as ESC.
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